WHWK Valuation

Whitehawk Therapeutics Inc

Add to Watchlist

Advanced Chart

1.810

+0.11(6.471%)1D

Overview
Forecast
Valuation
Earnings

WHWK Relative Valuation

WHWK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WHWK is overvalued; if below, it's undervalued.

Historical Valuation

Whitehawk Therapeutics Inc (WHWK) is now in the Fair zone, suggesting that its current forward PS ratio of 2.46 is considered Fairly compared with the five-year average of -2.25. The fair price of Whitehawk Therapeutics Inc (WHWK) is between 1.00 to 1.90 according to relative valuation methord.

Relative Value

Fair Zone

1.00-1.90

Current Price：1.81

Fair

-1.12

Trailing

Forward

0.00

EV/EBITDA

Whitehawk Therapeutics Inc. (WHWK) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

1.08

EV/EBIT

Whitehawk Therapeutics Inc. (WHWK) has a current EV/EBIT of 1.08. The 5-year average EV/EBIT is 1.48. The thresholds are as follows: Strongly Undervalued below -2.55, Undervalued between -2.55 and -0.53, Fairly Valued between 3.50 and -0.53, Overvalued between 3.50 and 5.52, and Strongly Overvalued above 5.52. The current Forward EV/EBIT of 1.08 falls within the Historic Trend Line -Fairly Valued range.

2.46

Whitehawk Therapeutics Inc. (WHWK) has a current PS of 2.46. The 5-year average PS is 2.32. The thresholds are as follows: Strongly Undervalued below 0.78, Undervalued between 0.78 and 1.55, Fairly Valued between 3.09 and 1.55, Overvalued between 3.09 and 3.86, and Strongly Overvalued above 3.86. The current Forward PS of 2.46 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Whitehawk Therapeutics Inc. (WHWK) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.63. The thresholds are as follows: Strongly Undervalued below -2.71, Undervalued between -2.71 and -1.67, Fairly Valued between 0.41 and -1.67, Overvalued between 0.41 and 1.44, and Strongly Overvalued above 1.44. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.98

P/FCF

Whitehawk Therapeutics Inc. (WHWK) has a current P/FCF of -0.98. The 5-year average P/FCF is -9.38. The thresholds are as follows: Strongly Undervalued below -26.78, Undervalued between -26.78 and -18.08, Fairly Valued between -0.69 and -18.08, Overvalued between -0.69 and 8.01, and Strongly Overvalued above 8.01. The current Forward P/FCF of -0.98 falls within the Historic Trend Line -Fairly Valued range.

Whitehawk Therapeutics Inc (WHWK) has a current Price-to-Book (P/B) ratio of 0.47. Compared to its 3-year average P/B ratio of 0.55 , the current P/B ratio is approximately -15.60% higher. Relative to its 5-year average P/B ratio of 0.55, the current P/B ratio is about -15.60% higher. Whitehawk Therapeutics Inc (WHWK) has a Forward Free Cash Flow (FCF) yield of approximately -117.66%. Compared to its 3-year average FCF yield of -78.11%, the current FCF yield is approximately 50.63% lower. Relative to its 5-year average FCF yield of -78.11% , the current FCF yield is about 50.63% lower.

0.47

P/B

Median3y

0.55

Median5y

0.55

-117.66

FCF Yield

Median3y

-78.11

Median5y

-78.11

Competitors Valuation Multiple

The average P/S ratio for WHWK's competitors is 0.49, providing a benchmark for relative valuation. Whitehawk Therapeutics Inc Corp (WHWK) exhibits a P/S ratio of 2.46, which is 400.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

WHWK.O

Whitehawk Therapeutics Inc

PMV Pharmaceuticals Inc

Loss

76.31M

QNCX.O

Quince Therapeutics Inc

Nautilus Biotechnology Inc

Loss

89.17M

Performance Decomposition

Market capitalization of WHWK increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.58 to -6.64.

The secondary factor is the Revenue Growth, contributed -100.00%to the performance.

Overall, the performance of WHWK in the past 1 year is driven by P/E Change. Which is more unsustainable.

-100.00%

6.18M → 0.00

Revenue Growth

-220.98%

-236.01 → 285.53

Margin Expansion

320.98%

-1.58 → -6.64

P/E Change

0.00%